Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Human CD19 Monoclonal Antibody

Catalog No.: YR0501

Basic Information

Molecular Weight
150 kDa

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SDS-PAGE

Background

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical PK and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone
Loncastuximab Biosimilar

Isotype
Human IgG1 kappa

Immunogen

RecommendedIsotype Control(s)

Recommended Dilution Buffer
1×PBS pH 7.3

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn


Product Information

Production
Purified from cell culture supernatant in an animal-free facility


Purification
Protein A or G purification

Storage
Store at -20℃

Validation Data



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD19 (Research Grade Loncastuximab Biosimilar) Monoclonal Antibody to CD19. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.



Human CD19 SPR assay. Determined through SPR assay, the Human Anti-Human CD19 (Research Grade Loncastuximab Biosimilar) Monoclonal Antibody is Capable of binding to Human CD19 with an affinity constant of 1.193n M.